Among the abovementioned immunotherapeutic agents, ICIs especially programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) have been frequently proven to be effective and safe in the immunotherapy of cancer including primary lung cancer, which is a well-known common and fatal cancer globally. This evidence concerns the gene CD274 and lung cancer.